<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727698</url>
  </required_header>
  <id_info>
    <org_study_id>CCR4841</org_study_id>
    <nct_id>NCT03727698</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment</brief_title>
  <acronym>PERMIT</acronym>
  <official_title>Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of PERMIT is to collect information on the treatment of radiotherapy patients
      using a new radiotherapy machine that includes magnetic Resonance (MR) imaging (MR linac) to
      guide treatment. The aim is to use this information to support the introduction of MR Linac
      into clinical practice.

      PERMIT will collect details on patients treated on the MR linac plus details on their side
      effects and other outcomes. This information plus technical and imaging information will be
      combined with information from other centres using this machine. By doing so this will help
      us learn how best to use the MR Linac in the future and design new radiotherapy protocols
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>To assess delivery of radiotherapy on the MR Linac for multiple tumour sites</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical feasibility of undertaking MRL based radiotherapy at multiple clinical sites: The percentage of treatment fractions delivered successfully on the MR linac</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of treatment fractions delivered successfully on the MR linac, if more than 20 % of patients (depending on treatment site) need to be treated on alternative machine or treatment protocol changed will lead to the MRL protocol at that site to be judged not feasible.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy delivered on the MR Linac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MR Guided radiotherapy treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR Linac</intervention_name>
    <description>MR guided radiotherapy treatment</description>
    <arm_group_label>Radiotherapy delivered on the MR Linac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Radiotherapy treatment suitable to be delivered on the MR Linac.

          2. Patient provides written, informed consent and/or authorization.

          3. Patients between the ages of 5 and under 16 years old may enter protocol with
             parental/guardian consent.

        Exclusion Criteria:

          1. Contra-indications to MR imaging.

          2. Radiotherapy not suitable for delivery on the MR Linac e.g. those with extended field
             lengths (exceeding 20 cm).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Huddart</last_name>
    <phone>44 208 661 3425</phone>
    <email>robert.huddart@icr.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorna Bower, BSc</last_name>
    <email>lorna.bower@icr.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Marsden NHSFT</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Huddart</last_name>
    </contact>
    <investigator>
      <last_name>Robert Huddart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised data will be shared within the academic and industrial partners. All data sharing would be dependant on appropriate data sharing agreements.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

